The findings back up laboratory tests that had suggested the vaccine would protect against variants first identified in South Africa and Britain.

Two studies showed the vaccine to be more than 95 percent effective at protecting against severe disease or death from the variants first identified in South Africa and the U.K.

We recognize that recommendations on alternative dosing intervals reside with health authorities and may include recommendations due to public health principles. However, as a biopharmaceutical...